423 related articles for article (PubMed ID: 30384581)
1. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
[TBL] [Abstract][Full Text] [Related]
2. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
Orucevic A; Bell JL; McNabb AP; Heidel RE
Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
[TBL] [Abstract][Full Text] [Related]
3. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
Orucevic A; Bell JL; King M; McNabb AP; Heidel RE
Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185
[TBL] [Abstract][Full Text] [Related]
4. Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis.
Marazzi F; Barone R; Masiello V; Magri V; Mulè A; Santoro A; Cacciatori F; Boldrini L; Franceschini G; Moschella F; Naso G; Tomao S; Gambacorta MA; Mantini G; Masetti R; Smaniotto D; Valentini V
Clin Breast Cancer; 2020 Oct; 20(5):e600-e611. PubMed ID: 32565110
[TBL] [Abstract][Full Text] [Related]
5. Correlation of Ki-67 proliferative index with oncotype DX recurrence score in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer with low-burden axillary nodal disease - a review of 137 cases.
Saad Abdalla Al-Zawi A; Anichkina KA; Elamass M; Aladili Z
Pol J Pathol; 2024; 75(1):8-18. PubMed ID: 38741425
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
Sughayer MA; Alhassoon S; Sughayer HM
Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
[TBL] [Abstract][Full Text] [Related]
7. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
8. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
9. Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer.
Yoo SH; Kim TY; Kim M; Lee KH; Lee E; Lee HB; Moon HG; Han W; Noh DY; Han SW; Kim TY; Im SA
Clin Breast Cancer; 2020 Apr; 20(2):98-107.e1. PubMed ID: 31522959
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer.
Baltres A; Al Masry Z; Zemouri R; Valmary-Degano S; Arnould L; Zerhouni N; Devalland C
Breast Cancer; 2020 Sep; 27(5):1007-1016. PubMed ID: 32385567
[TBL] [Abstract][Full Text] [Related]
11. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
[TBL] [Abstract][Full Text] [Related]
12. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
[TBL] [Abstract][Full Text] [Related]
13. A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer.
Lee YJ; Hwang YS; Kim J; Ahn SH; Son BH; Kim HJ; Ko BS; Kim J; Chung IY; Lee JW; Lee SB
Sci Rep; 2021 Dec; 11(1):23509. PubMed ID: 34873249
[TBL] [Abstract][Full Text] [Related]
14. In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry.
Tyburski H; Karakas C; Finkelman BS; Turner BM; Zhang H; Hicks DG
Lab Invest; 2024 Mar; 104(3):100309. PubMed ID: 38135156
[TBL] [Abstract][Full Text] [Related]
15. Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer.
Breaux A; Turner B; Wu X; Rai SN; Riley EC; Mandadi M; Sanders MA
Clin Breast Cancer; 2019 Feb; 19(1):e261-e269. PubMed ID: 30509870
[TBL] [Abstract][Full Text] [Related]
16. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer.
Vila J; Mittendorf EA; Farante G; Bassett RL; Veronesi P; Galimberti V; Peradze N; Stauder MC; Chavez-MacGregor M; Litton JF; Huo L; Kuerer HM; Hunt KK; Caudle AS
Ann Surg Oncol; 2016 Oct; 23(11):3501-3509. PubMed ID: 27216742
[TBL] [Abstract][Full Text] [Related]
17. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of the Detection of Lymphovascular Invasion in Hormone Receptor-Positive Early Breast Cancer in the Era of Molecular Profiling.
Mutai R; Goldvaser H; Shochat T; Peretz I; Sulkes A; Yerushalmi R
Oncology; 2019; 96(1):14-24. PubMed ID: 30253418
[TBL] [Abstract][Full Text] [Related]
19. The added value of ultrasound imaging biomarkers to clinicopathological factors for the prediction of high-risk Oncotype DX recurrence scores in patients with breast cancer.
Luo Y; Gao Y; Niu Z; Zhang J; Liu Z; Zhang Y; Shen S; Jiang Y; Xiao M; Zhu Q
Quant Imaging Med Surg; 2024 May; 14(5):3519-3533. PubMed ID: 38720854
[TBL] [Abstract][Full Text] [Related]
20. A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients.
Jin X; Jiang YZ; Chen S; Shao ZM; Di GH
Sci Rep; 2016 Aug; 6():32585. PubMed ID: 27576704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
